MedTrace Logo

The Effect of Metformin on Breast Cancer Patients

NCT04559308 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-09-22

No results posted yet for this study

Summary

Several clinical trials have addressed the promising anticancer effect of metformin on the survival benefits, clinical response, and pathological response of breast cancer patients.

Therefore, this study will assess the anticancer effect of metformin when added to the neoadjuvant chemotherapy protocol of non-diabetic breast cancer patients. In addition to, the impact of metformin addition to the neoadjuvant chemotherapy on the quality of life of breast cancer patients.

Conditions

Interventions

DRUG

Metformin

first-line anti-diabetic drug

DRUG

Chemotherapy

First line neoadjuvant chemotherapy protocol

Sponsors & Collaborators

  • Ahram Canadian University

    collaborator OTHER

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Ahmed A El Berry, Ph.D. · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-09-15
Completion
2020-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04559308 on ClinicalTrials.gov